Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 false

ליניאג' סל תרפיוטיקס אינק	2 380
.LINEAGE CELL THERAPEUTICS, INC
Corporation no: 876343	10834

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	26/02/2026
	www.isa.gov.il			www.tase.co.il				Reference:	2026-02-018416	Time of broadcast: 17:50 17:50

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

_and_Full_Year_2025_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: -1	Date of revision of form structure: 06/08/2024
Address: HARBOR BAY PARKWAY 1301 , ALAMEDA 94502   CALIFORNIA , U.S.A Tel: 5105213390 , Fax: 5105213389
E-mail address: info@biotimeinc.com   Company site: biotimeinc.com
Previous names of reporting entity: .BIOTIME, INC
Name of the Signatory: Gerzi SHNEOR Ilan Position of Signatory in the reporting corporation: Legal Adviser Name of Employer Company: PEARL COHEN ZEDEK LATZER BARATZ
Address: Derech Menachem Begin 121 , Tel Aviv 6701203 Telephone: 03-3039000 Facsimile: E-mail: igerzi@pearlcohen.com 1
U.S.A